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Summary
Combining data from a genomic screen in 70 families
with a high risk for prostate cancer (PC) with data from
candidate-region mapping in these families and an ad-
ditional 71 families, we have localized a potential he-
reditary PC-susceptibility locus to chromosome 1p36.
Because an excess of cases of primary brain cancer (BC)
have been observed in some studies of families with a
high risk for PC, and because loss of heterozygosity at
1p36 is frequently observed in BC, we further evaluated
12 families with both a history of PC and a blood relative
with primary BC. The overall LOD score in these 12
families was 3.22 at a recombination fraction (v) of .06,
with marker D1S507. On the basis of an a priori hy-
pothesis, this group was stratified by age at diagnosis of
PC. In the younger age group (mean age at diagnosis
!66 years), a maximum two-point LOD score of 3.65
at was observed, with D1S407. This linkage wasv  .0
rejected in both early- and late-onset families without a
history of BC (LOD scores 7.12 and 6.03, respec-
tively, at ). After exclusion of 3 of the 12 familiesv  .0
that had better evidence of linkage to previously de-
scribed PC-susceptibility loci, linkage to the 1p36 region
was suggested by a two-point LOD score of 4.74 at
, with marker D1S407. We conclude that a sig-v  .0
nificant proportion of these families with both a high
risk for PC and a family member with BC show linkage
to the 1p36 region.
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Introduction
Prostate cancer (PC) is the most common cancer (ex-
cluding nonmelanoma skin cancer) and the second lead-
ing cause of cancer deaths among men in the United
States. In 1998 alone, PC will have been newly diagnosed
in ∼184,500 men, and ∼39,000 men will die of the dis-
ease (Landis et al. 1998). PC incidence is highest among
men in their late 60s and 70s, with 23% of the total PC
population being men given a diagnosis at age !65 years
and with only 4% being men given such a diagnosis at
age !55 years (Stanford et al., in press).
Epidemiological data suggest that a strong familial
component is involved in the etiology of at least a subset
of cases of PC, particularly those diagnosed at younger
ages. A family history of PC in a first-degree relative is
associated with a significant two- to threefold elevation
in risk (Steinberg et al. 1990; Hayes et al. 1995; Whit-
temore et al. 1995). These results are supported by seg-
regation analyses (Carter et al. 1992; Gro¨nberg et al.
1997a; Schaid et al. 1998), which found that both early
age at onset and the presence of multiple affected family
members were strong predictors of risk in relatives. Car-
ter et al. (1992) proposed that inheritance of a rare,
autosomal dominant allele(s) ( ) with a high life-q  .003
time penetrance (88%) may explain PC incidence in
43% of early-onset cases (i.e., at age 55 years) and
∼9% of all cases of PC in the population. More recently,
a population-based segregation analysis estimated a
higher frequency of the dominant risk allele (q 
) and a lower lifetime penetrance, 63% (Gro¨nberg.0167
et al. 1997a).
Analyses of prostate tumors have suggested the pres-
ence of PC–susceptibility loci at a number of human
chromosomes, including regions of chromosomes 8, 10,
16, and 17 (Bova et al. 1993; Massenkeil et al. 1994;
Cher et al. 1996; Williams et al. 1996). Thus far, how-
ever, no PC–susceptibility locus has been revealed on any
of these chromosomes (Cannon-Albright and Eeles
1995), and genomewide screens of families with a high
risk for PC are ongoing. By using this approach, Smith
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et al. (1996) localized the first PC–susceptibility locus
(HPC1) to chromosome 1q24-25, by linkage analysis of
91 families with a high risk for PC that were from the
United States and Sweden. Smith et al. (1996) estimated
that germ-line mutations in HPC1 accounted for 34%
of PC in the families described. Families predicted to
carry mutations at this locus are reported to be enriched
for younger ages at diagnosis, higher-grade tumors, and
more advanced-stage disease at diagnosis (Gro¨nberg et
al. 1997b, 1997c), although the association with tumor
characteristics remains a topic of some debate (Laniado
1998). Although two sets of data provide confirmatory
evidence that HPC1 is responsible for PC susceptibility
in some families at high risk (Cooney et al. 1997; Hsieh
et al. 1997), in other data sets the linkage to HPC1 is
undetectable, suggesting that issues related to locus het-
erogeneity at 1q24-25 are not completely understood
(McIndoe et al. 1997; Berthon et al. 1998; Eeles et al.
1998). In all likelihood, the apparently contradictory
results may be reconciled, at least in part, if it is found
that HPC1 either contributes to markedly !34% of PC
in high-risk families or is disproportionately responsible
for disease in particular subsets of families.
Very recently, a second PC–susceptibility locus
(PCAP) was localized to 1q42.2-43 in a set of 47 French
and German families (Berthon et al. 1998), and another
(HPCX) has been mapped to the X chromosome (Xu et
al. 1998). Although findings reported by these investi-
gators await confirmation, it is clear that the loci de-
scribed thus far do not account for the majority of PC
in most high-risk families ascertained to date. Thus, ad-
ditional PC–susceptibility genes remain to be mapped.
Toward that end, we are continuing a genomewide
screen of families with a high risk for PC.
An initial analysis of our genomewide-screen data
highlighted chromosome 1p36. This region is of interest
in cancer genetics, for several reasons. Although it has
not been reported as a region of frequent loss of het-
erozygosity (LOH) in prostate tumors, it has been fre-
quently cited as a region of LOH for a variety of types
of brain tumors and CNS tumors (Bello et al. 1994b,
1995b; Schleiermacher et al. 1994; Kraus et al. 1995;
Maris et al. 1995; White et al. 1995; Kaghad et al. 1997).
Interestingly, epidemiological studies have found an as-
sociation between brain cancer (BC) and PC. Specifically,
Carter et al. (1993) reported that families with heredi-
tary PC have a significant excess of BC, and Isaacs et
al. (1995) showed that such families have a significantly
increased relative risk (RR) for tumors of the CNS (RR
3.02; 95% confidence interval [CI] 1.08–8.41). In a pop-
ulation-based family study, Goldgar et al. (1994) also
found an elevated RR of 1.25 (95% CI 1.0–1.5) for BC
and CNS cancer among first-degree relatives of PC pro-
bands. Thus, there appears to be a link between these
two seemingly unrelated types of cancer. We report here
on findings at 1p36, which appears to be responsible for
inherited disease in a defined subset of families with PC
that share a family history of primary BC.
Subjects and Methods
Ascertainment of Families with PC
A genomewide screen to map hereditary PC loci is
being conducted in families with a high risk that were
recruited nationwide as part of the Prostate Cancer Ge-
netic Research Study (PROGRESS). Participants from
eligible families are located throughout the United States,
Canada, and several other countries. Eligible families
must meet at least one of three criteria: three or more
first-degree affected relatives, PC in three generations,
and/or PC diagnosed in at least two affected siblings at
age 60 years. National advertising, media events, and
mailings to cancer support groups and urologists were
used to recruit families into the ongoing study, which
was initiated in July 1995. A toll-free number (1-800-
777-3035) has been established to screen potential par-
ticipants for their suitability. Once enrolled in the study,
both affected and selected unaffected male and female
family members are asked to provide a blood sample
and to complete a self-administered questionnaire that
obtains information on demographic factors, medical
history, family size and structure, and family history of
cancer. In addition, consent to access medical records
related to the diagnosis and treatment of cancer is re-
quested. All study procedures and forms are approved
by the institutional review board of the Fred Hutchinson
Cancer Research Center. Detailed procedures for contact
of families, selection of individuals for collection, iso-
lation of DNA, and genotyping have been summarized
elsewhere (McIndoe et al. 1997; authors’ unpublished
data).
Linkage Analysis
LINKAGE version 5.1 (Lathrop et al. 1984) was used
for two-point linkage analysis. Multipoint parametric
and nonparametric linkage (NPL) analyses used GENE-
HUNTER version 1.2 (Kruglyak et al. 1996). NPL
scores used were calculated by the NPLpairs option, be-
cause this is expected to be more robust to phenocopies
than is the NPLpairs option, as would be expected in a
common disease such as PC.
An admixture test for heterogeneity in the data set
was performed by HOMOG (Ott 1991). Parameters for
the autosomal dominant transmission models are de-
scribed in table 1. For both early-onset (!66 years) and
late-onset (66 years) pedigrees, the age-dependent pen-
etrance functions were estimated from our larger sample
of families with PC. The early-onset model was also used
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Table 1
Genotype-Specific Penetrances for Transmission Models
LIABILITY CLASS
FREQUENCY WHEN MEAN AGE AT DIAGNOSIS IS
!66 Years 66 Years
pp Pp PP pp Pp PP
1. All women, men age 25 years .000 .000 .000 .000 .000 .000
2. Men age 26–35 years .001 .004 .004 .001 .001 .001
3. Men age 36–45 years .001 .029 .029 .001 .001 .001
4. Men age 46–55 years .001 .134 .134 .001 .035 .035
5. Men age 56–65 years .001 .605 .605 .001 .213 .213
6. Men age 66–75 years .001 .909 .909 .001 .833 .833
7. Men age 76 years .025 .950 .950 .025 .950 .950
NOTE.—Allele P is associated with hereditary PC. Of the first 143 families (141 of which were
genotyped for this study), 13 were initially identified as having a related family member with
BC. Therefore, the gene frequency of .003 suggested by Carter et al. (1992) for all hereditary
PC was reduced to .00027 ( ). Men who reported that they had never had a PSA.003# [13/143]
test were coded as unknown. In the 12 families with BC, only cases of PC that were related by
blood to the person(s) with BC were considered to be affected, resulting in three cases of PC in
these 12 families being coded as unknown. Subjects with BC were coded as affected, with a
liability class of 2. Phenocopy rates in the analysis of all 141 families or of families without a
family member with BC were as used in the genomic scan; for liability classes 1–7, these rates
were .000, .001, .001, .005, .010, .050, and .050, respectively.
Table 2
Characteristics of 12 Families with PC and a History of BC
Category
and Family
No. of
Cases of PC
Mean Age at
Diagnosis of Sampled
Patients with PC
(years)
No. of
Cases of BC
Relationship between Cases
of PC and Cases of BC
Early-onset PC:
1 4 57.3 1a Second degree
2 5 63.5 2a First degree
3 5 64.0 1a Second degree
4 4 65.0 1a First degree
5 4 65.3 1a First degree
6 4 65.3 1a First degree
Overall 26 63.5 7 First degree (5), second degree (2)
Late-onset PC:
7 4 66.5 1a First degree
8 4 68.3 1 First degree
9 4 68.5 3b First degree
10 3 70.3 1a First degree
11 3 71.0 1 First degree
12 3 72.0 1a First degree
Overall 21 69.6 8 First degree
a Primary BC confirmed by medical records or death certificate.
b Two cases were confirmed by medical records or death certificate.
for subsequent analyses of a non–age-segregated data
set.
Under the hypothesis of a joint PC-BC locus, individ-
uals biologically unrelated to the patient with BC (i.e.,
those related only by marriage to the patient with BC)
would not be expected to show linkage to the same locus
as would be expected in patients biologically related to
individuals with BC. For this reason, three patients with
PC were coded as unknown. Because all coded affected
men were biologically related to the patient with BC, a
low phenocopy rate of .001 was used for all but the
oldest age class among the groups with PC-BC (table 1).
A relaxed age-dependent phenocopy rate was used for
analyses of families without a family history of BC (table
1). Subjects with BC but without PC were considered
affected; however, genotypes were available for only one
such person, and genotypes were inferred for another.
All three men with PC-BC were genotyped. The age at
onset of BC was not included in the mean age-at-onset
calculations; only the age at onset of PC was used. Fi-
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Table 3
Analysis of Six Families with Early-Onset PC-BC
Marker
Distance from
Preceding Marker
(cM)
Maximum
Positive
LOD Score (v) HLOD (v; a) NPLpairs (P)
D1S1160 ) .51 (.18) .62 (.00; .37) .522 (.284)
ATA9B08 2.74 .75 (.16) .75 (.16; 1.00) .950 (.172)
D1S489 6.58 .44 (.14) .45 (.08; .77) 1.177 (.124)
D1S1597 .10 .83 (.04) .89 (.00; .76) 1.351 (.096)
D1S434 .10 .83 (.00) .83 (.00; 1.00) 1.525 (.073)
D1S402 1.09 .90 (.14) .90 (.14; 1.00) 1.722 (.053)
D1S407 2.73 3.65 (.00) )a (.00; 1.00) 1.844 (.043)
D1S507 .10 2.81 (.04) 2.81 (.04; 1.00) 1.847 (.043)
GATA29A05 3.30 1.65 (.10) 1.65 (.10; 1.00) 1.817 (.045)
D1S552 8.28 1.02 (.12) 1.02 (.12; 1.00) 1.409 (.088)
a No evidence of heterogeneity was seen.
Table 4
Analysis of Six Families with Late-Onset PC-BC
Marker
Distance from
Preceding Marker
(cM)
Maximum
Positive
LOD Score (v) HLOD (v; a) NPLpairs (P)
D1S1160 ) .00 (.50) .00 (.50; 1.00) 1.520 (.941)
ATA9B08 2.74 .00 (.50) .00 (.50; 1.00) 1.554 (.941)
D1S489 6.58 .41 (.00) .41 (.00; 1.00) .128 (.497)
D1S1597 .10 .36 (.12) .36 (.00; .56) .397 (.656)
D1S434 .10 .63 (.00) .63 (.00; 1.00) .394 (.656)
D1S402 1.09 .12 (.24) .12 (.22; .86) .420 (.656)
D1S407 2.73 .11 (.22) .11 (.22; 1.00) .450 (.673)
D1S507 .10 .41 (.12) .41 (.12; 1.00) .449 (.673)
GATA29A05 3.30 .00 (.50) .00 (.50; 1.00) .471 (.673)
D1S552 8.28 .00 (.50) .00 (.50; 1.00) .468 (.726)
nally, in all families, men of age45 years who reported
being unaffected but who indicated either that they (1)
had not had a prostate-specific antigen (PSA) test during
the preceding 5 years, (2) did not know whether they
had ever had a PSA test, or (3) had an elevated PSA
level but did not have physician-diagnosed benign pro-
static hyperplasia were, for purposes of the analyses,
coded as unknown.
Results
Analysis of Genomewide Screen
The first set of 70 families to complete data collection
as part of PROGRESS was initially genotyped with 387
markers spanning the genome at an average resolution
of 10 cM. The genomewide scan involved a total of 512
genotyped individuals, of whom 247 were affected men.
Linkage analysis of these 70 families used a model that
was based on age-dependent penetrance values and that
closely followed the predictions by Carter et al. (1992).
Details of this model have been described elsewhere
(McIndoe et al. 1997). Although analysis of this and an
expanded data set of ∼150 families is still in progress,
an initial analysis of these first 70 families, made by
GENEHUNTER (Kruglyak et al. 1996), showed several
peaks with LOD scores 1.0. In the region described
here, we observed a peak multipoint LOD score under
the assumption of heterogeneity (HLOD) of 1.65 (pro-
portion of families estimated to be linked [a] .435) and
an NPL score of 2.13 ( ), in the short arm ofP  .02
chromosome 1. This peak was associated with one
marker, D1S1597. A two-point analysis with this marker
resulted in a maximum HLOD score of 0.89 at v  .0
and .v  .34
Stratification by age and/or other types of cancer has
been a useful method for isolation of homogeneous sub-
sets of families in efforts to map common disease genes
such as the BRCA1 breast-ovarian cancer gene (Hall et
al. 1990) and the BRCA2 breast cancer gene (Wooster
et al. 1994). The region defined by D1S1597 at 1p36 is
notable because it is associated with LOH in several
types of CNS tumors, and prior epidemiological studies
have shown a relationship between PC and cancer of
the CNS (Carter et al. 1993; Goldgar et al. 1994; Isaacs
et al. 1995). Therefore, we stratified our larger data set
of 141 families with PC, by mean age at diagnosis of
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Table 5
LOD and NPL Scores at D1S407, for 12 Families with PC-BC
Category
and Family
Mean Age at
Diagnosis of
Sampled Patients
with PC
(years)
LOD Score
at v  0
NPLpairs
Score (P)
Early-onset PC:
1 57.3 .49 .408 (.344)
2 63.5 .86 1.342 (.121)
3 64.0 .04 .001 (.422)
4 65.0 .32 1.463 (.156)
5 65.3 .46 .816 (.438)
6 65.3 1.49 1.301 (.156)
Overall 63.5 3.65 1.844 (.043)
Late-onset PC:
7 66.5 .30 .000 (.750)
8 68.3 .13 .805 (.438)
9 68.5 1.68 1.114 (.813)
10 70.3 1.09 .816 (1.000)
11 71.0 .52 .816 (.438)
12 72.0 .24 .816 (.438)
Overall 69.6 1.84 .450 (.673)
PC and the presence or absence of a family history of
primary BC. When the mean age at diagnosis among
sampled affected men was !66 years, families were con-
sidered “early onset”; families in which the mean age of
diagnosis among sampled affected men was 66 years
were considered “late onset.”
Families with PC-BC
Among the first 141 PROGRESS families, 38 were
identified in which one or more family members de-
scribed a family history of BC in an individual(s) related
by blood to the patient with PC. Because the brain is a
frequent site of metastasis (Ruddon et al. 1981), and
because the accuracy of familial cancer reporting is high-
est among first-degree relatives (Love et al. 1985;
Airewele et al. 1998), only those cases of BC that were
either confirmed by medical records or death certificates
or reported by two or more first-degree relatives were
included in the analysis, which reduced the data set to
12 families. Eleven of these families self-identified as
white, and one self-identified as nonwhite. For these 12
families, a total of 15 cases of primary BC were reported;
these included 9 gliomas, 1 CNS lymphoma, 2 malignant
brain tumors with unspecified histological type, and 3
with unknown histology for whom medical records have
been requested but not yet received. Twelve (80%) of
these 15 cases of BC have been validated by medical
records, including three men with PC who subsequently
developed primary BC. The CNS lymphoma occurred
in a family with a confirmed glioma and did not con-
tribute to the linkage result. The other 26 families ini-
tially reporting a member(s) with BC (29 cases) were
reclassified as not having invasive brain tumors, on the
basis of the following: (1) medical records confirmed
another primary site of cancer either with brain metas-
tases (6 cases) or with no mention of BC (8 cases); (2)
on subsequent follow-up, the cancers were determined
to be nonmalignant brain tumors (3 cases); or (3) cases
were not reported by at least two first-degree relatives
and have not been confirmed by medical records (12
cases).
Medical records were also requested, to verify the PC
diagnoses in these 141 families. To date, we have re-
ceived medical records for 459 (94.8%) of the 484 sam-
pled affected men; 99.8% verified the self-reported cases
of PC.
Two-Point Analysis of 12 Families with PC-BC
The mean age at diagnosis of PC in 141 families was
66.3 years. The 12 families with associated BC (table 2)
were separated according to the mean age at diagnosis
of PC in the 39 sampled affected men, resulting in 6
families with a history of BC and early-onset (mean age
!66 years) PC and 6 families with a history of BC and
late-onset (mean age 66 years) PC. The six families
with early-onset PC-BC had a total of 26 cases of PC,
with 21 of them genotyped. The mean age at diagnosis
of PC in genotyped affected men in the families with
early-onset PC was 63.5 years. A total of seven cases of
BC were reported in these families—five in first-degree
relatives of the patients with PC and two in second-
degree relatives of the patients with PC. Both of the
second-degree relatives with BC are related to the pa-
tients with PC through a female relative.
The six families with BC and late-onset PC had 21
family members with PC (18 were genotyped). The mean
age at diagnosis of the patients genotyped for PC in these
families was 69.6 years (table 2). A total of eight cases
of BC were reported in first-degree relatives of these
cases, including two men with PC and BC. One family
is notable for having three siblings with BC. The re-
maining 129 families with no confirmed cases of primary
BC were also divided by mean age at diagnosis of PC
(!66 years, 63 families; and 66 years, 66 families).
The 25-cM region surrounding D1S1597 was ana-
lyzed in detail, for linkage at 1p36. Separate transmis-
sion models were generated for the linkage analysis of
the two age-at-onset groups (table 1). For the six families
segregating BC and in which the average age at diagnosis
of PC was !66 years, a peak two-point LOD score of
3.65 at was observed, with D1S407 (table 3).v  .00
This marker is ∼4 cM from D1S1597, the marker for
which the original LOD score was noted in the ge-
nomewide screen. Although the maximum LOD scores
were positive across most of the same region for the six
families with late-onset BC (table 4), none was 11.0.
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Table 6
LOD Scores with D1S407, for Stratified Subsets of Families with PC
FAMILY HISTORY OF BC AND
MEAN AGE AT ONSET OF PC
NO. OF
FAMILIES
LOD SCORE AT v 
.00 .02 .04 .06 .08 .10 .20 .30 .40
Present:
!66 years 6 3.65 3.46 3.28 3.09 2.90 2.71 1.77 .90 .25
66 years 6 1.84 .87 .51 .30 .16 .07 .10 .08 .03
Absent:
!66 years 63 7.12 4.23 2.72 1.74 1.05 .55 .48 .44 .14
66 years 66 6.03 4.94 4.07 3.37 2.79 2.31 .82 .22 .03
Three of these families with late-onset PC did, however,
have positive LOD scores and haplotypes consistent with
linkage to this region (table 5).
When the 12 families are considered together, analysis
of all 12 families gave a peak LOD score of 3.22 at
, with D1S507, with no significant evidence forv  .06
heterogeneity. The closest adjacent marker, D1S407,
gave a LOD score of 2.57 at , which increasesv  .06
to 2.70 at when heterogeneity and arev  .0 a  .68
assumed. Linkage was rejected for the early-onset
( ) and late-onset ( ) families that did notn  63 n  66
have reported or confirmed cases of BC, with LOD
scores for D1S407 that were 7.12 and 6.02, respec-
tively, at (table 6). However, positive LOD scoresv  .0
were seen at higher v values for the early-diagnosis
non–BC group (maximizing at LOD score 0.53; v 
), suggesting a subset of linked families. Linkage was.24
similarly negative with marker D1S1597 for all 129 fam-
ilies with PC but without a family history of BC (data
not shown). Analysis using HOMOG and marker
D1S407 in all 141 families did not detect significant
evidence of heterogeneity. However, if one assumes het-
erogeneity, then a is estimated to be .15 when the model
for the 12 families is used. Because most of the 141
families do not have a member with BC, however, the
alternate model—that is, that for the families that do
not have BC—should be more appropriate; this model,
which differs in having higher phenocopy rates, results
in an estimate of . The wide range in the esti-a  .37
mates of a highlights the latter’s sensitivity to the model
chosen.
Multipoint Analyses
Multipoint linkage analysis with 10 markers, by
GENEHUNTER (Kruglyak et al. 1996), in the six fam-
ilies with BC and early-onset PC yielded a maximum
NPL score of 1.85 ( ) at a point correspondingP  .043
to the position of D1S507 (table 3). GENEHUNTER
does not use the complete information in all pedigrees,
and therefore this result may be an under-/overestimate.
The peak multipoint 10-marker HLOD score was 0.81
at , at a point between GATA29A05 anda  .72
D1S552, 6.59 cM away from the NPL peak. Multipoint
analysis of the smaller region of interest, including
D1S407–D1S552, yielded an NPL score of 2.24 (P 
) and an HLOD of 1.65 at and a LOD.020 a  .78
score of 1.48. The significant multipoint NPL score and
nonsignificant multipoint parametric-linkage score sug-
gested model misspecification. When, to test the sensi-
tivity to this parameter, the phenocopy rates were re-
laxed to match those used in the non–BC group, the
LOD and HLOD scores both equaled 2.33 ( ).a  1
The strongest NPL scores were observed for four ad-
jacent markers spanning a 6.1-cM region bounded by
D1S402 and GATA29A05, in which four adjacent mark-
ers had associated NPL scores with P values of ∼.05
(table 3). This is less than might be expected from the
positive two-point result over several adjacent markers.
However, the NPL score measures only haplotype shar-
ing among affected individuals; thus, linkage informa-
tion from older unaffected men is not represented. When
unaffected men are coded as unknown, the LOD score
drops from 3.65 to 2.83; that is, these men contributed
to ∼33% of the two-point LOD score. NPL scores
also may be underestimated in larger families that, be-
cause of computational limitations, had informative in-
dividuals dropped from analysis by GENEHUNTER.
To determine which set of families was most likely to
show linkage to each of the defined loci, the families
were specifically examined for possible linkage to the
HPC1 (1q24-25) and PCAP (1q42.2-43) regions (Smith
et al. 1996; Berthon et al. 1998). Two families (families
8 and 9) had positive LOD scores with marker D1S1589
in the HPC1 region that were higher than those with
marker D1S407, and two families (families 9 and 10)
had positive and higher LOD scores with marker
D1S2785 in the 1q42.2-43 region. Interestingly, all three
were late-onset families (table 7). If these three families
are excluded from the data set, analysis of the remaining
nine families, with no stratification by mean age at di-
agnosis of PC, yields a maximum LOD score of 4.74 at
( ), with D1S407, and a maximum NPLpairs scorev  .00
of 2.05 ( ) at a position corresponding toP  .027
D1S507 (table 8). The NPLall score for these nine families
was 1.57 ( ). These data suggest that linkage toP  .065
other defined PC–susceptibility loci, rather than mean
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Table 7
LOD Scores at Three Putative PC Loci, for 12 Families with
PC-BC
FAMILY
MAXIMUM ABSOLUTE LOD
SCORE WITH MARKERa
D1S407 D1S1589 (HPC1) D1S2785 (PCAP)
1 .49 .05 .03
2 .86 .24 .08
3 .04 .031 .28
4 .32 .16 .25
5 .46 .26 .84
6 1.49 .34 .38
7 .30 .18 .89
8b .13 .42 .19
9b 1.68 .28 .50
10b 1.09 .09 .22
11 .52 .46 .28
12 .24 .10 .14
a All LOD scores shown were maximal at , except forv  0
that for D1S1589 in family 3 (underlined), where .v  .08
b Showed stronger evidence of linkage at other defined loci.
Table 8
Nine Families with PC, Family History of BC, and No Evidence of Linkage to Either
HPC1(1q24-25) or PCAP (1q42-43)
Marker
Distance from
Preceding Marker
(cM)
Maximum
Positive
LOD Score a(v) HLOD (v; a) NPLpairs (P)
D1S1160 ) .17 (.26) .31 (.00; .21) .100 (.521)
ATA9B08 2.74 .46 (.22) .46 (.22; 1.00) .277 (.376)
D1S489 6.58 .87 (.10) .89 (.04; .77) 1.493 (.075)
D1S1597 .10 1.85 (.00) 1.86 (.00; .94) 1.654 (.057)
D1S434 .10 1.64 (.00) 1.64 (.00; 1.00) 1.801 (.043)
D1S402 1.09 1.73 (.10) 1.73 (.10; 1.00) 1.965 (.032)
D1S407 2.73 4.74 (.00) )b (.00; 1.00) 2.050 (.027)
D1S507 .10 3.84 (.02) )b (.02; 1.00) 2.052 (.027)
GATA29A05 3.30 2.04 (.08) 2.04 (.08; 1.00) 2.012 (.029)
D1S552 8.28 1.01 (.14) 1.01 (.14; 1.00) 1.541 (.069)
a Calculated by use of the early-onset PC-BC model.
b No evidence of heterogeneity was seen.
age at diagnosis, may account for the locus heterogeneity
observed even in this highly stratified subset of families.
Haplotype Analysis
Haplotypes for all 12 families are shown infigure 1.
Haplotype sharing is noted among all or nearly all af-
fected men in families 2, 4–7, 11, and 12. Families 8–10
had better evidence of linkage to other loci. Note that
three of the remaining families have a later average age
at onset. It is possible that some families in which all
affected men do not share a haplotype, such as family
3, nevertheless contain individuals who share a mutation
at this locus, and an occasional individual not sharing
a haplotype may simply reflect sporadic disease. We note
that family 9 has three cases of BC. Interestingly, this
family showed little sharing of haplotypes and a strongly
negative LOD score with D1S407 (fig. 1and table 5).
Given the infrequency of BC in the families with evidence
of 1p36 linkage, a high frequency of BC in one family
may suggest a separate genetic risk.
Discussion
We have identified by linkage analysis a chromosome
1p36 region that may contain a hereditary PC locus.
Susceptibility to common diseases such as PC is expect-
ed to be genetically heterogeneous. The putative
PC–susceptibility locus that the present study has iden-
tified at 1p36, together with those previously reported
at 1q24-25 (Smith et al. 1996), 1q42.2-43 (Berthon et
al. 1998), and the X chromosome (Xu et al. 1998), sug-
gest that this is the case in PC. Our data indicate further
that the locus at 1p36 is most strongly associated with
familial PC in kindreds that also have a history of BC.
Although the overall data set suggests that families
with an early age at diagnosis are more likely to show
linkage to the 1p36 region, several of the late-onset fam-
ilies suggest linkage to 1p36 as well. Interestingly, the
average age of the members of all three families that
show more positive LOD scores to either the 1q42-43
or 1q24-25 loci was greater; removal of these three fam-
ilies results in both a significant increase in the LOD
score, at 1p36, for the remaining families and some im-
provement of the overall NPL score, regardless of age
at diagnosis. This subset of nine families represents 75%
of the families with both a high risk of PC and a family
member with BC and represents 100% of those same
families in which the mean age at diagnosis of PC is !66
years. Of the 141 families, 6.4% were in this subset.
Some families lacking a history of primary BC may show
linkage to this locus as well; this could be due to un-

Figure 1 Haplotypes for 12 families. The order of markers is as listed in table 3. Inferred genotypes are italicized. The haplotype or haplotype segment most commonly shared by affected
pedigree members is outlined in men with known diagnoses. The age at diagnosis is given for affected individuals, whereas the age at sampling is given for unaffected men. To obscure the identity
of the pedigrees, pedigree members with uninformative diagnoses and many sisters of affected men have been omitted, except when it they have been necessary to show relationships; these omissions
include 39 genotyped individuals whose information was used to assist in haplotype construction. Also to obscure the identity of the pedigrees, vital status is not shown. X point of likely recombination.
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derreporting of BC by families, the inability to confirm
all cases of BC in the data set, or this allele’s weaker
penetrance for BC compared with PC.
The lack of statistical significance of the multipoint
parametric-linkage result may be due to model misspe-
cification. This explanation is consistent with (1) the
significance of the NPLpairs score at the .05 level; (2) the
6.59-cM difference, in the peak multipoint score, be-
tween the 10-point LOD score and the NPL score; and
(3) the improved LOD score when the sporadic rate is
relaxed. The significant two-point LOD score is unlikely
to be a false-positive result in the face of (a) positive
two-point LOD scores at multiple informative markers
over a 25-cM region (table 3) and (b) significant evidence
of haplotype sharing among affected men in the NPL
analysis. One cause of false-positive two-point LOD
scores is chance sharing of a rare or underestimated allele
at a marker. However, the families contributing to the
evidence of linkage here share different alleles at most
of the multiple markers suggesting linkage. In addition,
sharing of haplotypes would be inconsistent with a false-
positive two-point result based on the sharing of rare
marker alleles. Whereas two-point analysis relies on the
same model, it is known to be more robust to model
misspecification and locus heterogeneity than is multi-
point analysis (Risch and Giuffra 1992). In addition to
the inheritance pattern, areas that may contribute to
model misspecification include the sporadic rate, the age-
at-diagnosis penetrance functions, the disease-allele and
marker frequencies, and the map distances. In addition,
the multipoint HLODs are higher than the LODs, sug-
gesting that locus heterogeneity is affecting the power
to detect linkage.
We note that 14% (6/44) of the reported cases of BC
in our data set were found, by review of medical records,
to be metastases from other primary sites and that 18%
(8/44) were confirmed as other primary sites, with no
mention of BC in the medical or death records. Thus,
careful confirmation of BC phenotypic information will
be critical for follow-up studies.
We did not observe significant evidence for chromo-
some 1p36 linkage in the early- or late-onset families
that did not report a family history of primary BC. Thus,
there is not strong evidence to suggest that this chro-
mosomal region accounts for a significant portion of
hereditary PC in a family classically defined as “high
risk.” Some families without reported cases of BC may
be linked, however; identification of such families will
be difficult and likely will require characterization of an
actual disease gene.
We have compared the distribution of other types of
cancer—including colon, bladder, kidney, lung, pancre-
atic, breast, and ovarian cancer (the latter two in first-
degree relatives only)—in the 12 families with PC-BC
versus the 129 families without PC-BC, to determine
whether the families with PC-BC have a higher frequency
of other types of cancer. The cancer cases that were con-
sidered were those which had been reported by two or
more male blood relatives. No significant differences
were observed (in all comparisons, by Fisher’sP 1 .1
exact test).
All of the families with a confirmed tissue type had
at least one member with a neuroepithelial malignancy.
The majority of families in this data set had a family
history of glioma. The 1p36 region has been implicated
in multiple types of BC, including neuroblastomas
(Maris et al. 1995; Martinsson et al. 1995; Van Roy et
al. 1997), glioblastomas (Bello et al. 1995a), menin-
giomas (Bello et al. 1994a), oligodendrogliomas (Bello
et al. 1995b; Kraus et al. 1995), astrocytomas, and
mixed oligoastrocytomas (Ransom et al. 1992; Kraus et
al. 1995). Stratification either by tumor type or by age
at either diagnosis of BC or death, however, did not show
subsets of families that were more or less likely to be
linked. Stratification by family history of cancers at other
sites has not yet been done in the larger data set of 141
families, but there appears to be no obvious excess of
other tumor types in these 12 families.
The 1p36 region defined by D1S407 lies proximal to
the consensus deletion region in neuroblastomas, which
includes the p73 gene (Kaghad et al. 1997). Should this
linkage be confirmed in additional data sets, candidate
genes that localize to this region would encompass the
FGR oncogene and four genes—TNFR2, DAN, ID3
(heir1), and CDC2L1(p58)—excluded as the neuroblas-
toma tumor-suppressor gene (White et al. 1995).
Although epidemiological data have suggested a pos-
sible familial association between PC and BC (Carter et
al. 1993; Goldgar et al. 1994; Isaacs et al. 1995), we
are not aware of any previous reports of a genetic link
between PC and BC. PC is not known to be associated
with familial cancer syndromes with associated brain
malignancies such as von Hippel–Lindau or neurofibro-
matosis, and its primary metastatic site is bone (Ruddon
1981). One possible explanation for the genetic asso-
ciation observed here, therefore, is that there is at 1p36
a gene that functions as a type of general tumor sup-
pressor. Although its primary function is suppression of
PC, either weak penetrance of some mutations or certain
genetic backgrounds might lead to an increased inci-
dence of other types of cancer, such as BC. If so, our
data, which, admittedly, have been ascertained for PC,
suggest that mutants in the gene at 1p36 might be highly
penetrant for PC but weakly penetrant for BC. A similar
situation might account for the rare but statistically sig-
nificant frequency of cases of male breast cancer and
cases of colon cancer in families at high risk for breast
cancer, in which the disease is due to inherited mutations
in BRCA2 (Wooster et al. 1994). The increased fre-
quency of ovarian, prostate, and colon cancers in
786 Am. J. Hum. Genet. 64:776–787, 1999
BRCA1-linked families may also be the result of alleles
that are weakly penetrant for susceptibility at those sites
or in particular backgrounds (Ford et al. 1994). In ad-
dition, environmental exposures and epigenetic phenom-
ena may play a role in the frequency of CNS tumors or
brain tumors that are due to mutations in this putative
locus.
The association of brain tumors with LOH at 1p36,
together with a consideration that this locus may contain
a primary PC–susceptibility gene, may provide some in-
sight into the type of gene potentially responsible for
this PC-BC relationship. Clearly, establishment of a
PC–susceptibility gene at 1p36 awaits confirmation
through analysis of other, similar data sets. If this is
confirmed, we suggest the designation “CAPB,” for its
association with PC-BC. Should confirmation occur,
identification of the relevant gene should provide further
insight into both the problem of PC etiology and tumor
suppressors in general.
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